Combination of Drugs Already on Market Can Inhibit Bone Metastasis in Breast Cancer Patients
The researchers discovered that the killing activity of T-cells is inhibited by another type of immune cells and identified the proteins responsible for this effect. To neutralize these inhibitory proteins and reactivate the T-cells, they created a novel therapeutic combination that had never been tried before: a drug that counters the activity of the immune-inhibiting cells, along with an antibody that activates T-cells. [Press Release, Tel Aviv University]











